CLG will sell the StemArray products and services to its current customers and other companies and research institutions.
Enzo plans to validate the test in house and then seek approval in New York State to market it as an LDT.
The database will be available to researchers at 55 medical centers and universities supported by the Clinical and Translational Sciences Award from the National Institutes of Health.
The company will use GSG Mess-und Analysnegerate for marketing and distribution in Germany, Austria, and Switzerland.
Topin will create a marketing strategy around OnDose, prepare marketing materials, and conduct meetings to educate oncologists about the pharmacokinetic test.
QDx will develop, market, and process the QPredict Prostate Mitomic Test, which will be based on Mitomics' flagship mitochondrial DNA-based prostate cancer diagnostic.
The deal makes Bulldog the single source of Dualsystems' products in the US.
The agreement covers Conexio's SBT Resolver products, which are locus-specific PCR-based HLA sequencing-based typing reagents, and includes kits and analysis software.
According to Response Biomedical, the Canadian point-of-care market is expected to reach $66.2 million this year and to grow at 7 percent over the next few years.
Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.
NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.
Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.
In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.